Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Neratinib

A tyrosine kinase inhibitor of HER2, EGFR and HER4, approved in the United States in 2017 and in Europe in 2018 for early-stage HER2-positive breast cancer, as extended adjuvant therapy after trastuzumab. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?It forms a covalent, in other words permanent, bond with a cysteine in the HER2 and EGFR receptors: this is why it stays active even against the EGFR T790M variant, which escapes non-covalent inhibitors.

NeratinibGo to the active ingredient →
NeratinibActive ingredientNeratinibCat. No. P-N038-001CAS 698387-09-6
Neratinib-d6Isotopically labelledNeratinib-d6Cat. No. P-N038-002CAS 1259519-18-0

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.